Skip to main content

Table 6 Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 2/3

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Therapeutic schedule Total costs LY1 QALY2 Result
Peginterferon-alfa-2a + ribavirin $Brz 13,120 15.21 14.57 peginterferon-alfa-2a is dominant
Peginterferon-alfa-2b + ribavirin $Brz 17,465 15.11 14.32  
  1. Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.